Valye reports for unlimited access

Concord Acquisition Corp II is a Delaware-incorporated special purpose acquisition company (SPAC) trading on the OTCQX market under the ticker CNDA. The company holds cash and short-term investments and is focused on identifying and completing a business combination. As of the fiscal year ended December 31, 2025, the company reported net income but no revenue or operational segment data. The company extended its deadline to consummate a business combination to December 31, 2025. It recently changed its independent auditor from Marcum LLP to CBIZ CPAs P.C. with no reported disagreements.

Aldel Financial II Inc. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. The company’s business purpose is to merge, acquire, or combine with one or more businesses, with a focus on the financial services industry but without limitation to any sector or geography. The company completed its initial public offering (IPO) in October 2024, issuing 23 million units at $10 per unit, raising gross proceeds of $230 million, alongside private placements totaling approximately $7.175 million. The proceeds were placed primarily in a trust account invested in short-term U.S. Treasury obligations, with a small portion retained for working capital and expenses. As of the end of 2025, Aldel Financial II had not commenced operations or generated operating revenues, reflecting its status as an early-stage SPAC. The company’s shares and warrants trade on Nasdaq under the symbols ALDF, ALDF.U, and ALDF.W. The company’s financial statements show a strong liquidity position with a current ratio of 2.7 and cash ratio of 2.15 as of December 31, 2025. Net income reported for the year ended December 31, 2025, primarily reflects investment income on the trust account rather than operating activities. The company is subject to risks typical of SPACs, including the ability to identify and complete a business combination and potential conflicts of interest with its Sponsor and management.

SecureTech Innovations, Inc. is a technology company specializing in AI-driven manufacturing systems, blockchain infrastructure, and automotive safety technologies. It operates three primary segments: AI UltraProd, which delivers industrial 3D printing robotics and related services; Piranha Blockchain, focused on blockchain and cybersecurity platforms; and Terra Nova Technologies, which develops automotive safety products under the Top Kontrol brand. AI UltraProd's products serve construction, renewable energy, logistics, and warehousing sectors, offering integrated hardware, software, and technical support. Piranha Blockchain develops secure data centers and digital asset management solutions. Terra Nova Technologies is preparing for a spin-off of its automotive safety business. The company is expanding operations geographically and pursuing a NASDAQ uplisting.

Range Capital Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2024. Its business purpose is to identify and complete a business combination with one or more target companies, without limitation to industry or geography. The company has not yet identified or engaged with any target business and has not generated operating revenues. It completed an initial public offering in December 2024, raising gross proceeds of $100 million plus additional private placements and over-allotment proceeds, with approximately $115.6 million held in a trust account invested in short-term U.S. government securities. The management team is led by Tim Rotolo, who has experience in investment and operational roles across various sectors. The company plans to pursue a generalist acquisition strategy focusing on companies with scarce assets, pure play business models, and strong management, primarily in North America with enterprise values above $500 million. The company may use cash, debt, or equity to fund the business combination and may seek additional financing. As of December 31, 2025, the company reported no cash and cash equivalents outside the trust account, current assets of $417,317, and net income of $4,035,451 for the fiscal year. Basic and diluted EPS were -$0.01 for the third quarter of 2024. The company is an emerging growth and smaller reporting company, affecting disclosure requirements.

Braze, Inc. provides a cloud-based customer engagement platform that enables brands to deliver personalized messaging across multiple channels. Founded in 2011, the company has experienced rapid revenue growth in recent years but continues to operate at a net loss. Braze's platform depends on third-party cloud infrastructure and mobile operating systems, and the company invests heavily in technology development, sales and marketing, and international expansion. The business model relies on subscription renewals and expansion within existing customers, as well as attracting new customers. Braze faces a competitive market with established and emerging players and is subject to various operational and financial risks.

Rentokil Initial plc is a UK-incorporated public limited company specializing in pest control and hygiene and wellbeing services globally. The company operates over 2,000 facilities across 90 countries and has a significant presence in North America following its acquisition of Terminix Global Holdings in 2022. Its business model centers on protecting people from pest-borne diseases and poor hygiene risks, enhancing customer brand reputation, and pursuing sustainability in operations. The company invests in innovation with dedicated R&D centers, including the Rentokil Terminix North America Innovation Centre. Financially, Rentokil reported net income of $470 million USD for 2025 and maintains liquidity with a current ratio above 1.0. The executive leadership team oversees strategy execution and risk management. Recent market commentary and analyst reports highlight Rentokil as a key player in the business services sector with mixed analyst recommendations reflecting valuation debates [S1][N3][N5][N6].

Bright Mountain Media, Inc. is a digital advertising technology and media company that distributes content and advertising across various platforms. The company has experienced recurring losses and significant accumulated deficits, raising substantial doubt about its ability to continue as a going concern. It relies heavily on borrowings under a secured credit facility with Centre Lane Partners, which holds a significant ownership stake and controls the company's debt. The company’s revenues are concentrated among a few customers and are subject to seasonal fluctuations typical of the advertising industry. It faces risks from intense competition, rapid technological changes including AI, and challenges in maintaining effective internal controls. The company is actively exploring strategic alternatives including debt restructuring and capital raising to improve its financial position [S1].

Absci Corp is a biotechnology company that develops an Integrated Drug Creation platform combining AI, automation, and biologic drug discovery technologies. The platform is designed to accelerate the drug creation process by enabling efficient preclinical and clinical development activities. The company began commercial operations in 2018 and primarily generates revenue through partnerships involving drug creation activities rather than commercial product sales. Absci’s business model relies on advancing internally developed programs and partnering with third parties to generate milestone payments and royalties from product candidates discovered using its platform. As of late 2025, no partner has licensed intellectual property for clinical or commercial use, reflecting the early stage of the company’s commercial adoption. The company maintains operations internationally, including offices in Switzerland and Serbia, and faces typical risks associated with biologic drug development, regulatory approval, and supply chain dependencies.

BTC Development Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in April 2023. Its business objective is to identify and complete an initial business combination with one or more target companies, with a focus on businesses that can leverage bitcoin technology and treasury strategies. The company has not commenced operations beyond organizational activities, IPO, and target search. It completed its IPO on October 1, 2025, raising gross proceeds of $253 million, which are held in a trust account invested in U.S. government securities and money market funds. The company has a single reportable segment and evaluates performance at the corporate level. Management has prior experience with multiple blank check companies and business combinations in fintech and bitcoin-related sectors. The company incurs costs related to being a public company and due diligence activities. It has no revenues or operating history and does not expect revenues until after a business combination.

Willamette Valley Vineyards, Inc. produces and markets premium wines primarily from Oregon varietals including Pinot Noir, Pinot Gris, Chardonnay, Riesling, and Sparkling wines. The company operates vineyards, wineries, and tasting rooms, selling through direct-to-consumer channels (tasting rooms, wine clubs, internet sales) and distributors both in-state and out-of-state. Direct-to-consumer sales accounted for approximately 54.4% of revenue in 2025, with distributor sales making up the remainder. The company emphasizes growth in direct sales through hospitality centers and wine club memberships, though memberships decreased slightly in 2025. The company sold about 173,014 cases of wine in 2025, a 7.2% decline from 2024, reflecting lower sales across channels. The company invests in vineyard development and production capacity, operating two wineries with combined capacity exceeding current production. It faces competition from larger California wineries marketing Oregon-branded wines. The company has a revolving credit facility and maintains liquidity with a current ratio of 2.7 as of year-end 2025.

Andretti Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC) incorporated in May 2024 in the Cayman Islands. Its sole purpose is to identify and complete a Business Combination with one or more target companies. The company completed its IPO in September 2024, issuing 23 million Public Units and raising gross proceeds of $230 million, plus a private placement of 760,000 units. The proceeds are held in a trust account to be used for the Business Combination. The company has not generated operating revenues and does not expect to do so until after completing a Business Combination. The management team includes experienced executives and advisors with prior SPAC experience. The company’s acquisition strategy focuses on well-established companies with competitive advantages, strong management, attractive financial profiles, and growth potential. It has until September 9, 2026, to complete its initial Business Combination or face liquidation and distribution of trust account funds to shareholders. The company terminated a prior Business Combination agreement with StoreDot Ltd. in February 2026 and is seeking alternative transactions. Financially, as of December 31, 2025, the company holds cash and equivalents of approximately $876,000, current assets of $162,000, and current liabilities of $191,000, with a current ratio below 1.0 but a high cash ratio. Net income for the fiscal year ending December 31, 2025, was $8.35 million, with diluted EPS of $0.08 for Q3 2025. The company’s shares and warrants trade on Nasdaq under symbols POLE, POLEU, and POLEW.

G-III Apparel Group, Ltd. is a publicly traded company listed on the Nasdaq Stock Market under the ticker GIII. The company operates in the fashion industry, competing in intensely competitive markets. It maintains a strong liquidity position with a current ratio of 2.69 and cash ratio of 0.75 as of January 31, 2026. The company reported net income of $67.4 million and basic earnings per share of $1.58 for the fiscal year ended January 31, 2026. Recent corporate actions include the declaration of a quarterly cash dividend and the granting of long-term restricted stock unit awards to key senior leaders as part of succession planning and retention strategies. The company’s stock experienced a notable decline following Q4 earnings results that showed a year-over-year sales dip and a loss in the quarter, with market conditions also influenced by broader economic factors such as rising crude oil prices and geopolitical tensions.

Grayscale Sui Staking ETF is an investment trust that holds the SUI digital asset and engages in staking activities to generate returns for shareholders. The Trust operates within the digital asset ecosystem, which is characterized by high volatility, regulatory uncertainty, and evolving technology. The Sponsor oversees the Trust's operations, including cybersecurity and third-party risk management. The Trust's Shares trade on NYSE Arca and may trade at prices differing from the Trust's NAV due to market and liquidity factors. The Trust is subject to various risks including market volatility, regulatory changes, operational dependencies on third parties, and staking-related risks.

Blaize Holdings, Inc. is a Delaware corporation headquartered in El Dorado Hills, California, that develops AI-enabled computing solutions. Its product portfolio includes the GSP AI computing accelerator, compute cards, and a software suite including Blaize AI Studio. The company integrates third-party hardware, primarily servers, to provide comprehensive AI computing solutions for edge and data center deployments. Blaize also offers strategic consulting services. Manufacturing is fully outsourced to partners including Samsung Foundry and Plexus. Revenue is concentrated among a few customers, with a significant portion derived from third-party hardware sales. The company has not yet achieved profitability and has a history of operating losses. It holds a portfolio of patents related to AI and parallel processing. Blaize faces risks from customer concentration, supply chain dependencies, regulatory changes, and macroeconomic factors.

MV Oil Trust was formed in 2006 to hold a net profits interest in oil and natural gas properties owned by MV Partners, LLC. The Trust's interest entitles it to 80% of net proceeds from production of the underlying properties, which are located in Kansas and Colorado. The properties produce primarily oil from approximately 830 wells with long reserve lives. Operations are conducted by contract operators affiliated with MV Energy, LLC. The Trust itself has no employees and is managed by a trustee. Trust Units trade on the NYSE under the ticker MVO, with distributions made quarterly from net proceeds after expenses and reserves. The Trust is scheduled to wind up and terminate after June 30, 2026, at which point no further distributions will be made.

VOC Energy Trust was formed in 2010 to acquire and hold an 80% net profits interest in oil and natural gas properties owned by VOC Brazos Energy Partners, L.P. The Trust's interest entitles it to receive 80% of net proceeds from production and sales after deducting costs such as royalties, taxes, operating expenses, and development costs. The Trust does not operate the properties; operations are conducted by VOC Operators including Vess Oil Corporation. The Trust has no employees and is managed by a Trustee. The net profits interest is passive and will terminate on the later of December 31, 2030, or when specified production thresholds are met. The Trust Units trade on the New York Stock Exchange under the ticker VOC.

Strategic Storage Trust VI, Inc. is a Maryland-based real estate investment trust focused on investing in self storage facilities in the United States and Canada. Formed in 2020 and commencing operations in 2021, the company operates through an affiliated advisor and property manager, both subsidiaries of its sponsor, SmartStop REIT Advisors, LLC, itself an indirect subsidiary of SmartStop Self Storage REIT, Inc. The company owns a portfolio of 24 operating self storage properties across seven U.S. states and three Canadian provinces, along with two development properties and a 50% interest in five unconsolidated real estate ventures. Its properties offer month-to-month rental units to residential and commercial customers, featuring climate control, vehicle access, and security. The company leverages a technology-driven platform for marketing, pricing, and leasing, including digital and contactless rental options. It has multiple classes of common stock and preferred equity securities, with offerings conducted through private placements, public offerings, and distribution reinvestment plans. The company reported revenues of approximately $30.7 million and a net loss of $24.0 million for the fiscal year ended 2025-12-31, with cash and cash equivalents of $8.8 million. The company’s investment strategy emphasizes geographic diversification, property expansion, and professional management to improve profitability and cash flow sustainability.

Biomea Fusion, Inc. is a clinical-stage biotechnology company developing novel small molecule therapies primarily targeting metabolic disorders such as type 1 and type 2 diabetes and obesity, alongside oncology assets. Founded in 2017, the company has not yet commercialized any products or generated revenue. Its lead product candidate, icovamenib, is undergoing Phase II clinical trials for diabetes indications. The company also has BMF-650 in Phase I trials and BMF-500, an oncology asset, in early clinical development. Biomea Fusion utilizes its proprietary FUSION™ System platform for drug discovery. The company finances operations through equity offerings and has incurred significant net losses, reflecting ongoing research and development expenses. As of December 31, 2025, it held approximately $55.8 million in cash and equivalents, with strong liquidity ratios. The company has implemented a strategic realignment to focus on core diabetes programs and optimize its cash runway. It faces typical early-stage biotech risks including clinical, regulatory, financial, and operational challenges.

ECA Marcellus Trust I operates as a statutory trust owning royalty interests in natural gas properties primarily in the Marcellus Shale formation in Greene County, Pennsylvania. The Trust's assets include royalty interests in 14 producing wells and 40 development wells completed as of late 2025. The Trust does not engage in operational activities but receives cash flows from natural gas production after deducting post-production costs and administrative expenses. Greylock Production serves as the operator, and Greylock Midstream handles marketing and gathering. The Trust has a defined termination date in 2030, after which it will liquidate its assets. The Trust units represent passive interests with no control over operations or management.

LENZ Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia in adults. The product received FDA approval in July 2025 and was launched commercially in the United States in August 2025. The company has a limited operating history and has incurred significant net losses since inception, funding operations primarily through equity financing. LENZ's business model centers on the successful commercialization of VIZZ, with no other product candidates currently in development. The company has established licensing agreements with partners for commercialization in international markets such as South Korea and Greater China. Financially, as of December 31, 2025, LENZ held $25.2 million in cash and equivalents and maintained a strong liquidity position with a current ratio of 14.23. The company faces risks related to market acceptance of VIZZ, competition from other presbyopia treatments, reliance on third-party manufacturers and license partners, and the challenges inherent in scaling sales and marketing operations.

VirnetX Holding Corporation develops patented cybersecurity software and technology solutions designed to ensure secure, resilient communications across networks and devices. Its core products include VirnetX One™, a security-as-a-service platform based on Zero Trust Network Access principles, VirnetX Matrix™, which provides encrypted, identity-based access controls for enterprise applications, and VirnetX War Room™, a secure collaboration platform for sensitive communications. The company serves U.S. Department of Defense, federal government, and commercial customers across various sectors such as critical infrastructure, healthcare, financial services, and legal. VirnetX also engages in strategic partnerships, research collaborations, and international sales compliant with U.S. export regulations. The company is advancing its technology roadmap with developments in federated mesh networks, Model-Based Systems Engineering, and cyber threat intelligence services aligned with defense digital engineering strategies. As of December 31, 2025, VirnetX had 21 employees primarily focused on research and development.

Comstock Inc. is a company engaged in metals and recycling operations, including the development and expansion of end-of-life solar facilities in multiple U.S. states. The company also holds and sells mining-related royalties and is actively expanding its metals recycling network. It completed a significant public offering in early 2026 to support capital expenditures and growth initiatives. Financial disclosures indicate modest revenue with a substantial net loss as of the fiscal year ending December 31, 2025.

Fractyl Health, Inc. develops and plans to commercialize medical devices and gene therapy candidates targeting metabolic diseases such as obesity and type 2 diabetes. Its primary product candidate, Revita, is a device-based duodenal mucosal resurfacing procedure designed to improve metabolic health. The company is navigating regulatory pathways in the U.S., EU, and UK, including transitioning its device certification from the EU Medical Device Directive to the Medical Device Regulation and complying with UKCA marking requirements. Manufacturing depends on third-party sole-source suppliers without long-term agreements, posing supply chain risks. Clinical development includes ongoing studies in the U.S. and EU, with potential future studies outside the U.S. Fractyl Health has not generated revenue and reported significant net losses, reflecting its pre-commercial stage. The company’s sales cycle is expected to be lengthy and variable, involving multiple healthcare stakeholders and payors. Recent management changes and clinical data releases have been reported, alongside notable share price volatility.

BioCardia, Inc. develops cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases with significant unmet needs. Its primary platform, CardiAMP®, is an autologous mononuclear cell therapy aimed at treating ischemic heart failure with reduced ejection fraction and refractory angina due to chronic myocardial ischemia. The company also develops an allogeneic mesenchymal stem cell therapy for ischemic inflammatory heart failure and has an investigational program for acute respiratory distress syndrome. BioCardia's Helix™ transendocardial delivery system enables minimally invasive catheter-based delivery of therapeutics to the heart and is used both internally and in partnerships. The company has conducted multiple clinical trials, including pivotal and Phase III studies, with results showing safety and signals of efficacy in patient subgroups. Revenues are modest and derived mainly from partnering agreements and sales of FDA-cleared delivery devices. The company has incurred net losses since inception and relies on equity and convertible debt financing alongside grants to fund operations. [S1]

Neurogene Inc. focuses on developing gene therapies for severe neurological diseases with high unmet medical need. The company’s proprietary EXACT technology enables precise control of transgene expression via microRNA-based genetic circuits, aiming to overcome limitations of conventional gene therapy such as variable expression and toxicity. Founded in 2018, Neurogene has concentrated on research, clinical development, and establishing in-house manufacturing capabilities. Its lead candidate, NGN-401, targets Rett syndrome, a rare neurodevelopmental disorder caused by MECP2 gene mutations with a narrow therapeutic window for gene therapy. NGN-401 is delivered via intracerebroventricular infusion and is in Phase 3 clinical trials. The company has reported positive interim clinical data and operates a fully operational cGMP manufacturing facility in Houston, Texas. Neurogene has incurred significant losses since inception, with no approved products or commercial revenue, and plans to continue funding operations through capital raises and collaborations. The company collaborates with the University of Edinburgh and employs a team with expertise in gene therapy development and manufacturing.

GameStop Corp. is a specialty retailer established in 1996, offering games, collectibles, and entertainment products through thousands of stores and ecommerce platforms. The company operates in three geographic segments: United States, Australia, and Europe, having divested its Canadian operations in fiscal 2025. GameStop’s business model is evolving beyond traditional retail to include disciplined capital allocation aimed at value creation through acquisitions and control transactions. The company has focused on expanding its collectibles business, which grew to represent 29% of total sales in fiscal 2025, supported by initiatives such as graded trading card submission services and the launch of the Power Packs digital trading card platform in partnership with PSA. Store fleet optimization led to the closure of 727 U.S. stores in fiscal 2025, with no significant closures planned for fiscal 2026. The company continues to streamline international operations, including divestitures in Canada and New Zealand. Fiscal 2025 net sales declined 5.1% to $3.63 billion, driven by decreases in software and hardware sales but partially offset by a 47.7% increase in collectibles sales. Gross profit and margin improved due to a favorable sales mix. SG&A expenses decreased significantly due to cost optimization efforts. GameStop maintains a strong liquidity position with $6.3 billion in cash and $2.7 billion in marketable securities as of January 31, 2026. The company’s investment policy includes cash equivalents, fixed income, equity securities, and cryptocurrencies such as Bitcoin, which it holds as a treasury reserve asset. The company recorded losses related to its Bitcoin holdings due to market price declines and a covered call strategy. Management and the Audit Committee oversee cybersecurity risk and information security programs.

Commercial Bancgroup, Inc. is a bank holding company headquartered in Harrogate, Tennessee, operating primarily through its wholly owned subsidiary, Commercial Bank. The bank is a full-service community banking institution offering traditional consumer and commercial banking products and services to businesses and individuals in select markets across Tennessee, Kentucky, and North Carolina. As of December 31, 2025, the company operated 34 banking offices and one loan production office, with total consolidated assets of $2.3 billion, loans net of allowance of $1.9 billion, deposits of $1.8 billion, and shareholders' equity of $285.3 million. The company completed its initial public offering in October 2025, raising net proceeds of approximately $29.9 million. The bank's business strategy emphasizes growth through both acquisitions and organic expansion, focusing on superior customer service, market share growth in deposits and loans, and leveraging technology to enhance customer experience and operational productivity. The company targets small and medium-sized businesses, corporate customers, commercial real estate owners, and consumers, with a strong focus on relationship banking and core deposits to fund loan growth. The bank operates in a competitive environment with local, regional, and national financial institutions and non-bank financial service providers. Risk management is integral to the company's operations, with oversight by the board and committees on various risk exposures including credit, liquidity, interest rate, operational, compliance, cybersecurity, and reputational risks. The company maintains well-capitalized regulatory capital ratios and has made significant investments in technology platforms and employee development.

Fifth District Bancorp, Inc. was incorporated in February 2024 and became the holding company for Fifth District Savings Bank following its conversion from a mutual to stock form of organization in July 2024. The bank operates primarily in the New Orleans-Metairie Metropolitan Statistical Area through a main office and six branches. Its loan portfolio is predominantly fixed-rate one- to four-family residential mortgage loans, which accounted for 86.3% of total loans at year-end 2025. The company also originates and purchases commercial real estate, commercial and industrial loans, and other loan types. It retains most loans in its portfolio and emphasizes conservative underwriting standards, avoiding adjustable rate, interest-only, negative amortization, and subprime loans. Deposits are the primary funding source, with a focus on growing low-cost core deposits. The company offers a range of deposit accounts and electronic banking services. It is regulated by the Federal Reserve Board, OCC, and FDIC. At December 31, 2025, total assets were $534.4 million, loans $376.4 million, deposits $393.2 million, and stockholders’ equity $129.8 million. The company reported net income of $4.1 million and basic and diluted EPS of $0.80 for 2025. It faces strong competition in its market area from various financial institutions. The company recently authorized a buyback of up to 10% of outstanding shares [N1][S1].

Cayson Acquisition Corp operates as a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model centers on identifying and completing a merger or similar business combination with one or more target companies, primarily in Asia but without industry or geographic restrictions. The company raised gross proceeds of $60 million through its IPO and an additional $2.3 million via a private placement, with funds held in a trust account invested in U.S. government securities. It has not generated operating revenues and incurs costs related to formation, administration, and identifying a target. The company entered into a merger agreement with Mango Financial Limited in July 2025 and extended the deadline to consummate a business combination to March 2027. The company’s management includes CEO Yawei Cao and affiliated sponsors. The company’s financial position includes significant trust account assets but limited liquidity outside the trust account, with a current ratio of 0.12 as of December 31, 2025.

Curis Inc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of small molecule compounds targeting immuno-oncology and precision oncology. Its lead candidate, emavusertib (CA-4948), is an orally available inhibitor of IRAK4 and FLT3, developed under an exclusive collaboration with Aurigene Discovery Technologies Limited. The collaboration grants Curis options for exclusive licenses to develop and commercialize products globally, excluding India and Russia, with milestone and royalty payment obligations. The company previously derived revenues from royalties on Erivedge, a Hedgehog pathway antagonist licensed to Genentech, but sold its royalty interest in late 2025, ceasing related revenues. Curis finances operations through equity offerings, license fees, research funding, and royalty monetization. The company operates in a single segment focused on oncology drug development, with all assets located in the United States.

Brookfield Oaktree Holdings, LLC operates as a limited liability holding company primarily engaged in holding limited partner interests and capital commitments in Oaktree Opportunities Funds XI and XII, which are parallel investment vehicles or feeder funds. The company’s sole Class A unitholder contributes cash to fund these investments, and distributions from these investments benefit the Class A unitholder. The company accounts for its approximately 74% interest in Oaktree Capital I under the equity method following a 2024 restructuring. Revenue primarily consists of investment income from these funds and indirect ownership in Brookfield REIT. The company’s preferred units receive distributions generally serviced by distributions from Oaktree Capital I, but there is no guarantee of sufficient cash flow. The company’s operating agreement limits remedies available to preferred unitholders and modifies fiduciary duties of officers and directors. The company is not considered an investment company under the Investment Company Act, focusing on asset management services rather than investing or trading securities. The business depends on key personnel and services provided by Oaktree Capital Management and Brookfield, with risks related to regulatory compliance, investment leverage, liquidity, valuation, and tax complexities.

SUPA Consolidated Inc. is a Nevada-based company that has undergone multiple strategic transformations since its incorporation in 2014. Initially engaged in property tax lien services, the company shifted focus in 2020 to developing ridesharing and autonomous vehicle technologies, supported by patented software. In December 2024, SUPA sold its intellectual property and related assets to Boumarang Inc., receiving shares valued at $5 million, and discontinued its transportation technology operations. Subsequently, the company pivoted to the food technology sector, acquiring SUPA Food Services LLC in mid-2025, which operates commercial ice and water vending machines. The company is currently in a development phase, with no operating revenues and a business model centered on identifying, developing, and acquiring food technology assets. Operations are conducted through directors, officers, and third-party consultants, with no full-time employees as of the end of 2025.

ITHAX Acquisition Corp III is a Cayman Islands-based special purpose acquisition company (SPAC) that completed its initial public offering in December 2025, raising $230 million through the issuance of units consisting of Class A ordinary shares and redeemable warrants. The proceeds from the IPO and related private placements are held in a trust account. The company reported no revenue and a net loss of $56,044 for the fiscal year ended December 31, 2025. It maintains strong liquidity with a current ratio of 9.84 as of the same date. The company is classified as an emerging growth company and has entered into multiple agreements related to its IPO and warrant issuance. Detailed information on business operations, products, or customers has not been disclosed in the filings to date.

Millicom International Cellular S.A. (Millicom) is a leading telecommunications provider focused on emerging markets in Latin America. Operating under the Tigo brand, Millicom offers a broad range of mobile and fixed services, including mobile voice, data, SMS, mobile financial services (Tigo Money), broadband, pay-TV, fixed voice, and business solutions such as cloud and managed services. The company serves approximately 49.3 million mobile subscribers and 4.6 million fixed service customer relationships across Bolivia, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras (joint venture), Nicaragua, Panama, Paraguay, and Uruguay. Millicom’s infrastructure includes thousands of towers, extensive fiber networks, and data centers. The company’s strategy centers on expanding network capacity and distribution to increase penetration in under-served markets. Millicom reported $5.819 billion in revenue and $1.316 billion in net profit for 2025, with a strong liquidity position and ongoing capital investments to support network growth. The company’s organizational structure was streamlined recently to enhance operational focus and profitability.

Sanara MedTech Inc. develops and commercializes medical technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market. The company’s product portfolio focuses on soft tissue repair and bone fusion products used in operating rooms and sterile environments. Key products include CellerateRX Surgical Powder, a hydrolyzed collagen aiding surgical wound healing, and BIASURGE Advanced Surgical Solution, a sterile wound irrigation product with antimicrobial properties. Bone fusion offerings include BiFORM Bioactive Moldable Matrix and ALLOCYTE Plus Advanced Viable Bone Matrix. The company discontinued its Tissue Health Plus (THP) value-based wound care services program in 2025 due to persistent losses and lack of investor interest, refocusing solely on surgical products. Sanara MedTech operates a single reportable segment and relies on contract manufacturers for production. It has a commercial network covering over 4,000 hospitals and is expanding its geographic footprint in the U.S. The company is advancing a pipeline of next-generation products and has partnered to commercialize new technologies such as OsStic BioAdhesive. Recent clinical and preclinical studies support the efficacy and safety of its products. Financially, the company reported approximately $103 million in revenue for 2025 and a net loss of $37.6 million, including discontinued operations related to THP. Sanara MedTech holds a strong leadership team with experience in the surgical market.

Titan America SA, incorporated in Belgium in 2024 and majority owned by Titan SA, is a leading vertically integrated manufacturer and supplier of heavy building materials in the US Southeast and Mid-Atlantic regions. The company operates two reportable segments: Florida and Mid-Atlantic, each encompassing cement production, aggregates mining, ready-mix concrete, concrete block manufacturing, fly ash processing, and related logistics including marine import terminals and rail infrastructure. The Florida segment includes the Pennsuco cement plant, the largest in Florida by capacity, and the Port Tampa Bay Terminal, a key import and storage facility. The Mid-Atlantic segment includes the Roanoke cement plant, the only cement plant in Virginia, and terminals in Norfolk and Essex serving the Mid-Atlantic and Metro New York markets. Titan America emphasizes sustainability through production of lower-carbon cement, use of alternative fuels, and recycling initiatives. The company completed its IPO in February 2025 and reported net income of $185.4 million for the fiscal year ended December 31, 2025. It maintains strong liquidity and continues to invest in growth, productivity, and maintenance capital expenditures.